BMO Capital raised the firm’s price target on Ingevity (NGVT) to $68 from $62 and keeps an Outperform rating on the shares. The company announced the sale of its CTO Refinery and most of the InSpec business in its Performance Chems platform for a solid high-teens multiple, and the firm sees this reducing earnings volatility and improving the margin profile of the business, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGVT: